Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Incidence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

12 evidence topics · 10 sources

U.S. share of cases that are HR-positive/HER2-negative, SEER 21, 2019 to 2023
SubtypePercent of cases
HR+/HER2-“70%”
HR-/HER2-“11%”
HR+/HER2+“9%”
HR-/HER2+“4%”
Unknown“6%”
U.S. stage distribution at diagnosis, SEER 21
Stage at diagnosisPercent of cases
Localized“64%”
Regional“27%”
Distant“6%”
Unknown“2%”
U.S. new metastatic female breast cancer cases, 2018 estimate and 2025 projection
MeasureBreast (female)
Number of new metastatic cancer cases, de novo (observed), 2018“15 800”View highlighted excerpt for this quote
Number of new metastatic cancer cases, de novo and recurrence (estimated), 2018“46 666”View highlighted excerpt for this quote
Projected number of new metastatic (de novo and recurrence) cancer cases, 2025“52 126”View highlighted excerpt for this quote